METASTATİK PROSTAT KANSERİNDE CYPROTERONE ACETATE VE KASTRASYON MONOTERAPİLERİNİN ETKİNLİĞİNİN KARŞILAŞTIRMASI: ÇOK MERKEZLİ BİR TÜRK ÜRO-ONKOLOJİ GRUBU ÇALIŞMASI

Abstract

Amaç: İlerlemiş prostat kanserinde tibbi veya cerrahi kastrasyon ile CPA’yi karşılatırmak ve CPA’nin terapötik etkisini ortaya koymak. Gereç ve Yöntem: Ondokuz Üroloji Merkezi’ne başvuran T1-4N+MX veya T1-4NXM+ evreli prostat adenokanserli hastalar çalışmaya alınmıştır. Toplam 120 hasta, CPA 3X100mg/gün (Grup1) ve tıbbi veya cerrahi kastarasyon (Grup 2) gruplarına rastgele dağıtılmışlardır. Bu denemenin birincil son noktaları genel ve hastalığa-özel sağkalım olasılıklarıdır. Progresyonsuz sağkalım (PSA progresyon zamanı) ve testesteron düşüş hızı ikincil son noktalar olarak kabul edilmiştir.Progresyonsuz sağkalım olasılıkları Kaplan-Meier metoduyla hesaplanmış ve Logrank testiyle de sağkalım olasılıkları karşılaştırılmıştır.

Anahtar Kelimeler: Prostat kanseri,CPA,Kastrasyon,PSA-progresyon,Sağkalım

Keywords

• Prostat kanseri,CPA,Kastrasyon,PSA-progresyon,Sağkalım

References

1. 1. Anderson J. Treatment of prostate cancer-The role of primary hormonal therapy. Eur Urol 2003; 132-139.
2. 2. Huggins C, Hodges CV. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1:293-297.
3. 3. The Veterans Administration Co-operative Urological Research Group (1967) Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967;124:1011-1017.
4. 4. Vogelzang NJ, Chodak GW, Soloway MS, et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer:final results of a randomized trial; Zoladex Prostate Study Group. Urology 1995; 46:220-226.
5. 5. Kaisary AV, Tyrell CJ, Peeling WB, Griffiths K (1997) Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostate carcinoma. Br J Urol 1997; 32:391-396
6. 6. Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Lancet 2000;355:1991-1998.
7. 7. Anderson J. The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU, European Urology Update Series 2003; 9:455-461.
8. 8. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: Current status and future prospects. The Prostate 2004; 61:332-353.

9. 9. Iversen P, Melezinek I, Schmidt A. Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. BJU International 2001; 87:47-56.
10. 10. Maatman TJ, Gupta MK, Montie JE. Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate. J Urol 1985;133:620-621.
11. 11. Chodwick DJ,Gillatt DA,Gingell JC.Medical or surgical orchiectomy:The patients’ choice.BMJ1991; 302:372.
12. 12. The Leuprolide Study Group Group. Leuprolide versus diethylstillbestrol for metastatic prostate cancer. N Eng J Med 1984; 311:1281-1286.
13. 13. Chang A, Yeap B, Davis T, et al. (1996) Doubleblind,randomized study of primary hormonal teratment of stage D2 prostate carcinoma: Flutamide versus diethylstilbestrol. J Clin Oncol 1996; 14:2250-2257.
14. 14. Labrie F, Belanger A, Susan L, et al. History of LHRH agonist and combination therapy in prostate cancer. Endoc Relat Cancer 1996; 3:243-278.
15. 15. Stege R. Potantial side effects of endocrine treatment of long duration in prostate cancer. Prostate 2000; (Suppl 10):38-42.
16. 16. Miyomoto H, Chang C. Antiandrogens fail to block andrositenedione-mediated mutated androgen receptor transactivation in human prostate cancer cells. Int J Urol 2000; 7:32-34.
17. 17. Galler J. Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer. Semin Oncol (Suppl 1) 1985;12::28-35.
18. 18. Schröder FH. Endocrine treatment of prostate cancerrecent developments and the future. Part 1: MAB, early vs delayed endocrine treatment and side-effects. BJU International 1999; 83:161-170.
19. 19. Crawford ED, Eisenberger MA, Spaulding JT, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Eng J Med 1989;321:419- 424.
20. 20. Denis LJ, Whelan P, deMoura JCL, et al. Goserelin acetate and flutamide versus bilateral orchiectomy: A phase III EORTC trial (30853). Urology 1993;42:119- 132.
21. 21. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Eng L Med 1998; 339:1036-1042 .
22. 22. Tyrrell CJ, Kaisary AV, Iversen P et al. A randomized comparison of Casodex (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33:447-456.
23. 23. Iversen P, Tyrrell CJ, Kaisary AV, et al. Casodex (bicalutamide) 150 mg-monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer:results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998; 51:389-396.
24. 24. Boccardo F, Barichello M, Battaglia M, et al. Italian Prostate Cancer Group.Bicalutamide monotherapy versus Flutamide plus Goserelin in Prostate Cancer: Updated results of a multicentric trial. Eur Urol 2002; 42:481-490.
25. 25. Sciarra A, Cardi A, DiSilverio F. Antiandrogen monotherapy: recommendations for the treatment of prostate cancer. Urol Int 2004; 72:91-98.
26. 26. Goldenberg SL, Bruchovsky N. Use of ciproterone acetate in prostate cancer. Urol Clin North Am 1991;18:111-112.
27. 27. Pavone-Macaluso M, de Voogt HJ, Viggiano G., et al. Comparison of DES, CPA and medroxyprogestrone acetate in the treatment of advanced prostatic cancer:final analysis of a randomized phase III trial of the European Organization for research on treatment of cancer urological group. J Urol 1986;136:624-631.
28. 28. Moffat LE. Comparison of Zoladex, DES and CPA treatment in advanced prostate cancer. Eur Urol 18(Suppl 3):26-27.
29. 29. Thorpe SC, Azmatullah S, Fellows GJ, O’Boyle PJ. A prospective, randomized study to compare goserelin acetate versus cyproterone acetate versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol 1996; 29:47-54.
30. 30. Appu S, Lawrentschuk N, Grills RJ, Neerhut G. Effectiveness of CPA in achieving castration and preventing LHRH analogue induced testosterone surge in patients with prostate cancer. J Urol 2005;174:140- 142.
31. 31. Schröder FH, Whelan P, de Reijke TM, et al. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the EORTC protocol 30892. Eur Urol 2004;45:457-464.